Nature Reviews Cancer POSTER - MITOCHONDRIAL FUNCTION AND CANCER Author: Douglas C. Wallace
This Poster highlights some recent discoveries that have led to a renewed interest in the function of mitochondria in cancer cells. Mitochondria carry out a number of crucial functions in cells and these can be altered through mutations in either the nuclear DNA or the mitochondrial DNA.
Antibody alarm call rouses immune response to cancer doi:10.1038/486016a Trial drug outperforms earlier efforts to marshall the body's defences to combat tumours. Full Text
Deal watch: Shire increases focus on regenerative medicine doi:10.1038/nrd3767 Shire has agreed to buy Pervasis Therapeutics in a deal worth up to US$200 million, gaining its most advanced programme: an endothelial cell-based product known as Vascugel that is in Phase II trials in patients with end-stage renal disease. Full Text
Deal watch: Amgen builds secondary hyperparathyroidism pipeline doi:10.1038/nrd3768 Amgen to pay US$315 million for Kai Pharmaceuticals, whose candidate KAI-4169 is set to begin Phase III trials for treating secondary hyperparathyroidism in patients with chronic kidney disease, and could join Amgen's cinacalcet for this indication. Full Text
Patent watch: Changes in Australian patent law doi:10.1038/nrd3751 Australia has introduced several amendments to its intellectual property legislation intended to result in greater consistency with other major patent jurisdictions such as the United States and the European Union. Full Text
Channel-tuning neuropathy doi:10.1038/scibx.2012.564 Researchers have shown that a methylglyoxal-scavenging peptide treated painful diabetic neuropathy in mice by preventing structural changes to a sodium channel in peripheral neurons. The team is seeking venture capital to spin out the findings into a new company. Full Text
Pipeline pioneers: Vismodegib doi:10.1038/nrd3753 First-in-class inhibitor of the Hedgehog signalling pathway approved in the United States for the treatment of basal cell carcinoma. Full Text
From the analyst's couch: Outlook for the next 5 years in drug innovation doi:10.1038/nrd3744 Analysis of industry pipeline data and revenue forecasts highlights several trends in the anticipated output of new drugs and the therapeutic area focus over the next 5 years, including a growth in the average number of new drug approvals annually. Full Text
Neurological disorders: Nanoparticle opens door to cerebral palsy treatment doi:10.1038/nrd3758 Polyamidoamine dendrimers have been used to effectively deliver an anti-inflammatory drug to the brain of a rabbit model of cerebral palsy, resulting in improved motor function. Full Text
Bone diseases: SEMA3A strikes a balance in bone homeostasis doi:10.1038/nrd3759 Researchers have identified semaphorin 3A as a dual regulator of osteoclasts and osteoblasts, and suggest that this could provide a strategy to address limitations of existing osteoporosis drugs that target osteoclast activity. Full Text
Therapeutics: Iterations of BRAF doi:10.1038/nrc3284 Röring and colleagues investigate the involvement of the dimer interface in the ability of RAF to mediate downstream signalling, with implications for targeting BRAF. Full Text
Are sirtuins viable targets for improving healthspan and lifespan? doi:10.1038/nrd3738 This article provides an overview of the sirtuin family, focusing on sirtuin 1 and its potential to be targeted in the treatment of age-related diseases. Full Text
Spatial regulation of receptor tyrosine kinases in development and cancer doi:10.1038/nrc3277 This Review discusses how dysregulation of the spatial control of receptor tyrosine kinase (RTK) activity might contribute to tumorigenesis and affect the sensitivity and resistance of cancers to pharmacological RTK inhibitors. Full Text
Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing doi:10.1038/nbt.2214 Whitehead et al. demonstrate that computational design followed by comprehensive energy landscape mapping can generate proteins with potential therapeutic utility. Full Text
Direct and selective small-molecule activation of proapoptotic BAX doi:10.1038/nchembio.995 A computational screen identifies a small-molecule activator of proapoptotic BAX that selectively binds to the BAX trigger site, inducing characteristic conformational changes, oligomerization and BAX-dependent cell death. Full Text
Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment